SEP ? 8 1007

LET OF REPERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY DOCKET NO. Y2428-00065	APPLICATION NO. 10/582,256		
APPLICANT Flath et al.			
FILING DATE  March 5, 2007	GROUP 4645 1611		

## **U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	2003/0143269 A1	7/31/03	Oshlack et al.			
	A02	2003/0157168	8/21/03	Breder et al.			
	A03	3,493,657	2/3/70	Lewenstein et al.			
	A04	3,773,955	11/20/73	Pachter et al.			
	A05	3,966,940	6/29/76	Pachter et al.			
	A06	4,457,933	7/3/84	Gordon et al.			
	A07	4,582,835	4/15/86	Lewis et al.			
	A08	4,880,585	11/14/89	Klimesch et al.			
	A09	4,957,681	9/18/90	Klimesch et al.			
	A10	5,073,379	12/17/91	Klimesch et al.			
	A11	5,266,331	11/30/93	Oshlack et al.			
	A12	5,324,351	6/28/94	Oshlack et al.			
	A13	5,334,392	8/2/94	Cuine et al.			
	A14	5,356,467	10/18/94	Oshlack et al.			
	A15	5,451,409	9/19/95	Rencher et al.			
	A16	5,462,747	10/31/95	Radebaugh et al.			
	A17	5,472,712	12/5/95	Oshlack et al.			
	A18	5,492,692	2/20/96	Digenis et al.			
	A19	5,508,042	4/16/96	Oshlack et al.			
	A20	5,549,912	8/27/96	Oshlack et al.			
	A21	5,656,295	8/12/97	Oshlack et al.			
	A22	5,935,975	8/10/99	Rose et al.			
	A23	5,958,452	9/28/99	Oshlack et al.			
	A24	5,965,161	10/12/99	Oshlack et al.			
	A25	5,968,551	10/19/99	Oshlack et al.			
	A26	6,063,405	5/16/00	Drizen et al.			
	A27	6,120,802	9/19/00	Breitenbach et al.			
	A28	6,143,328	11/7/00	Heafield et al.			
	A29	6,228,863	5/8/01	Palermo et al.			
	A30	6,294,195	9/25/01	Oshlack et al.			
	A31	6,306,391	10/23/01	Modi et al.			
	A32	6,335,033	1/1/02	Oshlack et al.			
. ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	A33	6,696,088	2/24/04	Oshlack et al.			
	A34	7,144,587	12/5/06	Oshlack et al.			

		FOREIG	N PATENT DOCUMENTS				
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL	ATION
						YES	NO
B01	WO 2004/026283	4/1/04	PCT				
B02	WO 2004/093819	11/4/04	PCT				

	OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)
C01	Osol, A (ed.) Remington's Pharmaceutical Sciences (1980) pp. 1553-1593
C02	Remington's Pharmaceutical Sciences 18 <sup>th</sup> ed. (1990) pp. 1684-1685

EXAMINER	/Kyle Purdy/	DATE CONSIDERED	03/05/2008
*EXAMINER: Ini	tial if reference considered, whether or not cit	tation is in conformance with MPEP 609; Draw line the	hrough citation if not in conformance and not

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.	APPLICATION NO:
Y2428-00065	10/582,256
APPLICANT	
Flath et al.	
FILING DATE	GROUP
M	1611

## **U.S. PATENT DOCUMENTS**

*EXAMINATION INITIAL	MATRI	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	2003/0143269 A1	7/31/03	Oshlack et al.			•
	A02	2003/0157168	8/21/03	Breder et al.			
	A03	3,493,657	2/3/70	Lewenstein et al.			
	A04	3,773,955	11/20/73	Pachter et al.			
	A05	3,966,940	6/29/76	Pachter et al.			
	A06	4,457,933	7/3/84	Gordon et al.			
····	A07	4,582,835	4/15/86	Lewis et al.			
	A08	4,880,585	11/14/89	Klimesch et al.			
	A09	4,957,681	9/18/90	Klimesch et al.			
	A10	5,073,379	12/17/91	Klimesch et al.			
	A11	5,266,331	11/30/93	Oshlack et al.			
	A12	5,324,351	6/28/94	Oshlack et al.			
	A13	5,334,392	8/2/94	Cuine et al.			
	A14	5,356,467	10/18/94	Oshlack et al.			
	A15	5,451,409	9/19/95	Rencher et al.			
	A16	5,462,747	10/31/95	Radebaugh et al.			
	A17	5,472,712	12/5/95	Oshlack et al.			
	A18	5,492,692	2/20/96	Digenis et al.			
	A19	5,508,042	4/16/96	Oshlack et al.			
	A20	5,549,912	8/27/96	Oshlack et al.			
	A21	5,656,295	8/12/97	Oshlack et al.			
	A22	5,935,975	8/10/99	Rose et al.			
	A23	5,958,452	9/28/99	Oshlack et al.			
	A24	5,965,161	10/12/99	Oshlack et al.			
	A25	5,968,551	10/19/99	Oshlack et al.			
	A26	6,063,405	5/16/00	Drizen et al.			
	A27	6,120,802	9/19/00	Breitenbach et al.			
	A28	6,143,328	11/7/00	Heafield et al.			
	A29	6,228,863	5/8/01	Palermo et al.			
	A30	6,294,195	9/25/01	Oshlack et al.			
	A31	6,306,391	10/23/01	Modi et al.			
	A32	6,335,033	1/1/02	Oshlack et al.			
	A33	6,696,088	2/24/04	Oshlack et al.			
	A34	7,144,587	12/5/06	Oshlack et al.			

		FOREIG	N PATENT DOCUMENTS				
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL	ATION
						YES	NO
B01	WO 2004/026283	4/1/04	PCT				
B02	WO 2004/093819	11/4/04	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)					
C01	Osol, A (ed.) Remington's Pharmaceutical Sciences (1980) pp. 1553-1593				
C02	Remington's Pharmaceutical Sciences 18 <sup>th</sup> ed. (1990) pp. 1684-1685				

EXAMINER	/Kyle Purdy/	DATE CONSIDERED	03/05/2008
l			

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.